Materials and General Methods. Reagents for peptide synthesis and Rink amide resin (100-200 mesh, 0.54 mmol/g) were purchased from Chem-Impex (Wood Dale, IL). Fmoc-D-Thr-(PO(OBzl)OH)-OH was purchased from NovaBiochem (La Jolla, CA). Cell culture media (DMEM) was purchased from Life Technologies. Fetal bovine serum and penicillin-streptomycin were purchased from Invitrogen (Carlsbad, CA), while 0.25% trypsin-EDTA and DPBS were purchased from Sigma. The purity of the peptides was assessed by analytical HPLC and the identity was confirmed by MALDI-TOF mass spectrometric analyses on a Bruker UltrafleXtreme MALTI-TOF-TOF (Campus Chemical Instrument Center, The Ohio State University) instrument (unless noted otherwise).
S2
DMF (3 times each), the peptides were incubated with 1 M HOBt for 30 min. Peptide cyclization was effected by incubating the resin with PyBOP/HOBt/DIPEA (10, 10, 30 equiv. respectively) for 30 min (twice). The cyclic peptides were cleaved by treating with 92.5% TFA, 2.5% H2O, 2.5% TIPS, and 2.5% dimethoxybenzene (DMB) for 3 h. After solvent evaporation, the crude peptides were triturated with cold diethylether and purified by HPLC. The purified peptide (~0.5 mg) was dissolved in 50 µL of DMSO and the pH was adjusted to ~9 with the addition of 1 M NaHCO3. Ten µL of FITC (100 mg/mL) in DMSO was added to the peptide and the mixture was incubated for 1 h. The labeled peptide was purified again by reversed-phase HPLC on a C18 column. The HPLC tracings and MS spectra for each peptide are shown in Fig. S1 .
IC50
Determination by Fluorescence Anisotropy. The competition assay was carried out by incubating 50 nM FICT-labeled peptide 1 with 100-400 nM MBP-Pin1 in PBS containing 2 mM TCEP for 30 min. The mixture was then added to serially diluted peptide (0-25 µM) and incubated for 90 min. The FA values were recorded on a Molecular Devices Spectramax M5 spectrofluorimeter, with excitation and emission wavelengths at 470 and 530 nm, respectively. The IC50 was determined by plotting FA values against the peptide concentration and data fitting using the four-parameter dose response inhibition equation (Prism 6, GraphPad).
Flow Cytometry. HeLa cells were seeded in 6-well plates at a density 1.5 x 10 5 cells per well overnight. Next day, 5 µM FITC-labeled peptide 15 or 16 was added in DMEM media supplemented with 1% FBS and 1% penicillin/streptomycin sulfate for 2 h. After 2 h, the media was removed, and the cells were washed with cold DPBS and harvested by incubating with 0.25% trypsin for 5 min. The detached cells were washed with DPBS, suspended in DPBS, and analyzed by flow cytometry (BD FACS Aria III), with excitation at 535 nm.
MTT Cell Viability Assay. HeLa cells were seeded in a 96-well plate at a density of 5000 cell/well (100 µL in each well) in DMEM supplemented with 10% FBS and 1% penicillin/streptomycin sulfate overnight. Next day, peptide was added to the cells and incubated in 5% CO2 incubator at 37 o C for 72 h, during which the growth media was replaced with fresh media containing the peptide every 24 h. 10 µL of MTT solution (5 mg/mL) was added to each well and incubated for 2 h. 100 µL of the SDS-HCl solubilizing buffer was added to each well and the contents were carefully mixed by pipetting up and down. The plate was incubated for 4 h and the absorbance of the solubilized formazan was measured on a Molecular Devices Spectramax M5 plate reader at 570 nm.
Immunoblotting. HeLa cells were seeded in a 6-well plate with standard DMEM supplemented with 10% FBS and 1% penicillin-streptomycin sulfate at 37 ℃ in 5% CO2 to reach 90% confluence. The cells were treated with peptide 11 (0-10 μM), peptide 2 (10 μM) or 1% DMSO (vehicle control) in serum-free DMEM for 2 h. FBS was then added to a final concentration as 10% and cells were grown for additional 22 h. The cells were harvested by washing twice with cold PBS, detaching by treatment with 0.25% Trypsin-EDTA solution, and combining all of the fractions. After centrifugation in a microcentrifuge (5000 rpm, 5 min), cell pellets were lysed on ice for 30 min in IP lysis buffer containing protease and phosphatase inhibitors. Cell lysates were centrifuged at 15000 rpm for 10 min, and the extracted proteins in the supernatant were collected. Protein concentrations were measured by using BCA Protein Assay Kit (Thermo, 23235), and equal amounts of protein were loaded onto a 10% SDS-PAGE gel. The proteins were transferred S3 electrophoretically to a nitrocellulose membrane at 4 ℃. The membrane was first blocked with 10% nonfat dry milk in TBST (0.1% (v/v) Tween 20 in 1x TBS) for 1 h, followed by incubating with anti-PML (Santa Cruz sc-5621) or anti-β-actin (Sigma A5441) overnight at 4 ℃. The membranes were washed three times with TBST and incubated with corresponding HRPconjugated secondary antibodies for 2 h at room temperature, followed by washing with TBST three times and proceeding to detection immediately. The signals were detected by using Chemiluminescent HRP Antibody Detection Reagent (Denville, E-2500) by following the manufacturer's protocol. S4 Fig. S1 . Peptide purification by reversed-phase HPLC (semi-preparative), purity assessment by analytical HPLC, and MALDI-TOF mass spectrometry.
FITC-labeled peptide 1:
Crude peptide 1 before labeling with FITC (semi preparative reversed-phase HPLC)
Crude FITC-labeled peptide 1 (semi preparative reversed-phase HPLC) C. Data presented are the mean ± SD from three independent experiments (after subtraction of background signal derived from "blank"). MFI, fluorescence intensity.
